静脉注射免疫球蛋白联合甲泼尼龙与单用免疫球蛋白对儿童多系统炎症综合征发热病程的关联
该回顾性队列研究基于法国国家监测系统,纳入111例符合世界卫生组织(WHO)定义的儿童多系统炎症综合征(MIS-C)患儿,比较初始治疗使用静脉注射免疫球蛋白(IVIG)联合甲泼尼龙与单用IVIG的疗效。主要终点为治疗开始后2天发热持续或7天内发热再燃(定义为治疗失败)。倾向性评分匹配分析显示,联合治疗组治疗失败风险显著低于单用IVIG组(绝对风险差 -0.28 [95% CI, -0.48 to -0.08];OR 0.25 [95% CI, 0.09 to 0.70];P = .008),且二线治疗、血流动力学支持、急性左心室功能障碍及儿科重症监护室住院时间均显著降低。作者认为,在MIS-C患儿中,IVIG联合甲泼尼龙较单用IVIG与更有利的发热病程相关,但研究解释受观察性设计限制。
要点
- 在111例符合WHO定义的MIS-C患儿中,IVIG联合甲泼尼龙组治疗失败3/34(9%),单用IVIG组37/72(51%),联合治疗与较低治疗失败风险相关(OR 0.25 [95% CI, 0.09 to 0.70];P = .008)。
- 联合治疗组二线治疗风险显著低于单用IVIG组(绝对风险差 -0.22 [95% CI, -0.40 to -0.04];OR 0.19 [95% CI, 0.06 to 0.61];P = .004)。
- 联合治疗组血流动力学支持风险显著低于单用IVIG组(绝对风险差 -0.17 [95% CI, -0.34 to -0.004];OR 0.21 [95% CI, 0.06 to 0.76])。
- 联合治疗组初始治疗后急性左心室功能障碍风险显著低于单用IVIG组(绝对风险差 -0.18 [95% CI, -0.35 to -0.01];OR 0.20 [95% CI, 0.06 to 0.66])。
- 联合治疗组儿科重症监护室住院时间中位数4天,单用IVIG组6天,差异为 -2.4天(95% CI, -4.0 to -0.7)。
适用人群与场景
- 来自法国国家监测系统的疑似MIS-C病例,经确认符合世界卫生组织(WHO)定义并纳入分析的儿童。
- 纳入111例患儿(58例女性[52%];中位年龄8.6岁[四分位距,4.7至12.1])。
- 研究起始于2020年4月1日,随访截止于2021年1月6日。
诊断标准与关键阈值
- MIS-C诊断采用世界卫生组织(WHO)定义。
- 治疗失败定义为初始治疗开始后2天发热持续或7天内发热再燃。
处置流程与药物剂量
- 初始治疗比较:静脉注射免疫球蛋白(IVIG)联合甲泼尼龙 vs 单用IVIG。
研究设计与关键结果
- 研究类型:回顾性队列研究,采用倾向性评分匹配分析,匹配卡钳值最小为0.1。
- 样本量:181例疑似MIS-C患儿中111例符合WHO定义;5例未接受任一治疗;最终分析中IVIG联合甲泼尼龙组34例,单用IVIG组72例。
- 主要终点:治疗失败在联合治疗组为3/34(9%),单用IVIG组为37/72(51%);联合治疗与较低治疗失败风险相关(绝对风险差 -0.28 [95% CI, -0.48 to -0.08];OR 0.25 [95% CI, 0.09 to 0.70];P = .008)。
- 次要终点:二线治疗风险降低(绝对风险差 -0.22 [95% CI, -0.40 to -0.04];OR 0.19 [95% CI, 0.06 to 0.61];P = .004);血流动力学支持风险降低(绝对风险差 -0.17 [95% CI, -0.34 to -0.004];OR 0.21 [95% CI, 0.06 to 0.76]);初始治疗后急性左心室功能障碍风险降低(绝对风险差 -0.18 [95% CI, -0.35 to -0.01];OR 0.20 [95% CI, 0.06 to 0.66]);儿科重症监护室住院时间中位数4天 vs 6天,差异 -2.4天(95% CI, -4.0 to -0.7)。
证据类型、等级与局限
- 证据类型:回顾性队列研究,采用倾向性评分匹配分析。
- 局限:研究解释受观察性设计限制。
对床旁实践的改变
- 在符合WHO定义的MIS-C患儿中,初始治疗采用IVIG联合甲泼尼龙较单用IVIG与更有利的发热病程相关(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Multisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy remains unknown.
OBJECTIVE: To compare intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone as initial therapy in MIS-C.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study drawn from a national surveillance system with propensity score-matched analysis. All cases with suspected MIS-C were reported to the French National Public Health Agency. Confirmed MIS-C cases fulfilling the World Health Organization definition were included. The study started on April 1, 2020, and follow-up ended on January 6, 2021.
EXPOSURES: IVIG and methylprednisolone vs IVIG alone.
MAIN OUTCOMES AND MEASURES: The primary outcome was persistence of fever 2 days after the introduction of initial therapy or recrudescence of fever within 7 days, which defined treatment failure. Secondary outcomes included a second-line therapy, hemodynamic support, acute left ventricular dysfunction after first-line therapy, and length of stay in the pediatric intensive care unit. The primary analysis involved propensity score matching with a minimum caliper of 0.1.
RESULTS: Among 181 children with suspected MIS-C, 111 fulfilled the World Health Organization definition (58 females [52%]; median age, 8.6 years [interquartile range, 4.7 to 12.1]). Five children did not receive either treatment. Overall, 3 of 34 children (9%) in the IVIG and methylprednisolone group and 37 of 72 (51%) in the IVIG alone group did not respond to treatment. Treatment with IVIG and methylprednisolone vs IVIG alone was associated with lower risk of treatment failure (absolute risk difference, -0.28 [95% CI, -0.48 to -0.08]; odds ratio [OR], 0.25 [95% CI, 0.09 to 0.70]; P = .008). IVIG and methylprednisolone therapy vs IVIG alone was also significantly associated with lower risk of use of second-line therapy (absolute risk difference, -0.22 [95% CI, -0.40 to -0.04]; OR, 0.19 [95% CI, 0.06 to 0.61]; P = .004), hemodynamic support (absolute risk difference, -0.17 [95% CI, -0.34 to -0.004]; OR, 0.21 [95% CI, 0.06 to 0.76]), acute left ventricular dysfunction occurring after initial therapy (absolute risk difference, -0.18 [95% CI, -0.35 to -0.01]; OR, 0.20 [95% CI, 0.06 to 0.66]), and duration of stay in the pediatric intensive care unit (median, 4 vs 6 days; difference in days, -2.4 [95% CI, -4.0 to -0.7]).
CONCLUSIONS AND RELEVANCE: Among children with MIS-C, treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. Study interpretation is limited by the observational design.
参考来源
- Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021. PMID: 33523115. doi:10.1001/jama.2021.0694
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。